Genmab A/S (NASDAQ:GMAB) Sets New 1-Year Low - What's Next?

Genmab A/S (NASDAQ:GMAB - Get Free Report)'s share price hit a new 52-week low during trading on Tuesday . The stock traded as low as $19.27 and last traded at $19.08, with a volume of 38725 shares trading hands. The stock had previously closed at $20.80.

Analyst Ratings Changes

GMAB has been the subject of several recent analyst reports. Sanford C. Bernstein raised Genmab A/S from a "strong sell" rating to a "hold" rating in a research note on Friday, December 20th. HC Wainwright reiterated a "buy" rating and issued a $50.00 price objective on shares of Genmab A/S in a research note on Thursday, January 23rd. BMO Capital Markets reissued an "outperform" rating and set a $48.00 target price (up from $46.00) on shares of Genmab A/S in a research note on Friday, November 8th. Finally, Redburn Atlantic assumed coverage on shares of Genmab A/S in a research note on Tuesday, October 8th. They issued a "buy" rating for the company. Three equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $45.20.

Genmab A/S Trading Down 5.9 %

The stock has a market capitalization of $12.96 billion, a P/E ratio of 19.01, a price-to-earnings-growth ratio of 0.57 and a beta of 0.97. The business has a fifty day simple moving average of $21.09 and a 200 day simple moving average of $23.87.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last released its quarterly earnings results on Wednesday, November 6th. The company reported $0.29 earnings per share for the quarter, missing the consensus estimate of $0.32 by ($0.03). The firm had revenue of $816.10 million for the quarter, compared to analysts' expectations of $838.20 million. Genmab A/S had a return on equity of 14.64% and a net margin of 23.49%. During the same quarter last year, the firm posted $0.47 earnings per share. As a group, research analysts forecast that Genmab A/S will post 1.28 earnings per share for the current year.

Institutional Trading of Genmab A/S

Several hedge funds have recently added to or reduced their stakes in the stock. Legacy Wealth Asset Management LLC boosted its position in Genmab A/S by 1.1% during the third quarter. Legacy Wealth Asset Management LLC now owns 44,979 shares of the company's stock worth $1,097,000 after purchasing an additional 471 shares during the period. China Universal Asset Management Co. Ltd. lifted its stake in shares of Genmab A/S by 10.3% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,891 shares of the company's stock valued at $186,000 after buying an additional 827 shares in the last quarter. GAMMA Investing LLC boosted its holdings in Genmab A/S by 96.6% in the 4th quarter. GAMMA Investing LLC now owns 2,139 shares of the company's stock worth $45,000 after buying an additional 1,051 shares during the period. Eagle Asset Management Inc. grew its stake in Genmab A/S by 10.0% in the 3rd quarter. Eagle Asset Management Inc. now owns 12,356 shares of the company's stock valued at $285,000 after buying an additional 1,121 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC raised its holdings in Genmab A/S by 43.6% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 4,653 shares of the company's stock valued at $113,000 after acquiring an additional 1,413 shares during the period. Institutional investors own 7.07% of the company's stock.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.